This site is intended for healthcare professionals
News

FDA approves Crysvita for the treatment of fibroblast growth factor 23 -related hypophosphatemia in tumor-induced osteomalacia (TIO) Ultragenyx + Kyowa Kirin Co., Ltd.

Read time: 1 mins
Last updated:19th Jun 2020
Published:19th Jun 2020
Condition: Hypophosphatemia
Type: drug
Register free for full access to medthority.com